Xenex Healthcare Services announces it has been awarded Frost & Sullivan’s 2012 U.S. New Product Innovation Award in Hospital and Safety Prevention Technologies. A “green,” mercury-free technology, Xenex offers a fast, safe and cost-effective method for the automated disinfection of healthcare facilities.
"Xenex is being recognized with the Frost & Sullivan 2012 New Product Innovation Award in Hospital Safety and Prevention Technologies because more than any other available technology, the Xenex system is able to provide superior effectiveness in disinfection along with functionality that is easy to learn and operate," says Venkat Rajan, industry manager, Frost & Sullivan. "Hospitals that have implemented use of the Xenex system have documented immediate reduction in the presence of drug-resistant microorganisms. Beyond the clinical benefit, facilities have noticed an immediate return on investment through various patient care and operational cost savings. The innovative elements of Xenex's cutting-edge room disinfection system make it stand out from other technologies and systems and we are proud to present them with this well-deserved award."
Xenex’s portable room disinfection system uses pulsed xenon ultraviolet light to destroy viruses, bacteria and bacterial spores in the patient environment without contact or chemicals. Uniquely designed for ease of use and portability, a hospital’s environmental services staff can operate the Xenex device without disrupting hospital operations or requiring the use of expensive chemicals. The Xenex system will disinfect over thirty (30) rooms per day, so hospitals use the system continuously to reduce contamination levels throughout their facilities.
“We have proven repeatedly that the science of our pulsed xenon light makes it incredibly effective against the most challenging bacteria, viruses and even C. diff spores,” says Mark Stibich, chief scientific officer of Xenex. “Xenex customer Cooley Dickinson Hospital just presented a study which showed they had a 53 percent reduction in hospital acquired C. diff when the Xenex device was used to disinfect patient rooms at discharge, operating rooms, emergency rooms, and other areas as available. In another recent study, Cone Health reported that their MRSA rates dropped 56 percent in 2011 after they implemented an infection prevention program including Xenex’s device.”
“Xenex’s mission is to save lives and reduce suffering by preventing healthcare associated infections. Hospitals using our room disinfection devices are experiencing fewer infections and are able to provide a safer environment for their patients, staff and visitors,” says Morris Miller, CEO of Xenex. “We applaud Frost & Sullivan for acknowledging that HAIs are a national health crisis and presenting their findings, after conducting exhaustive research, that our device is superior to other technologies for helping hospitals combat this problem.”
Xenex devices are made in the U.S. and friendlier to the environment than current housecleaning chemicals or other UV devices using toxic mercury. Xenex is the only company to offer a xenon-based room disinfection product that is patented, tested, and proven to deliver a germicidal dose of UV-C light capable of killing C. diff in five minutes or less. Xenex systems, currently in use by hospitals throughout the U.S., have proven to be effective against a variety of the most dangerous superbugs, including Clostridium difficile endospores (C. diff), MRSA, VRE, and Acinetobacter. Studies show the Xenex room disinfection system is consistently 20 times more effective than standard chemical cleaning practices and a recent study performed at MD Anderson Cancer Center demonstrated that the Xenex system was more effective than bleach in reducing C. diff. in patient rooms.